JAKARTA. Philip Morris International Inc (PMI), the parent company of PT HM Sampoerna Tbk (HMSP), has secured a deal to acquire Fertin Pharma A/S for USD 820 million or equal to IDR 12 trillion.
Jacek Olczak, CEO of Philip Morris, claims that acquiring this pharmaceutical company would be a significant step to attaining a smoke-free future. “Fertin’s capability would help to enhance our smoke-free portfolio, more specifically in the modern oral category, and accelerate our transition towards products besides nicotine goods,” Olczak explains to idnfinancials.com.
Olczak also reveals that PMI and Fertin currently hold the same commitment. Fertin is well-known as a company experienced in developing nicotine substitute products for therapy. From this acquisition, PMI would gain expertise support from 80 scientists to invent smoke-free products.
“I am beyond glad for securing this deal, which would enrich our capability and support our mission in 2025 to have over 50% of our revenue coming from smoke-free products, and at least USD 1 billion from products besides nicotine,” Olczak further elaborates.
Meanwhile, Mindaugas Trumpaitis, President Director of HMSP, is optimistic that this acquisition would offer alternative products with lower risk for adult smokers. “In Sampoerna, we sincerely hope to introduce smoke-free products to the Indonesian market,” Trumpaitis adds. (KR/ZH)